Metagenomi Therapeutics Inc (MGX) Stock Analysis

AI analysis of Metagenomi Therapeutics Inc (MGX)

Sell

Metagenomi Inc (MGX) is not a good buy right now due to its significant financial struggles and negative market sentiment. The current price is $0.70, which is near its 52-week low of $0.60, reflecting a staggering year-to-date change of -57.99%. Additionally, the RSI is at 26.455, indicating that the stock is oversold, but this does not guarantee a rebound. The company reported a Q1 EPS of -0.61, missing expectations, and has a forward P/E ratio of 0, suggesting no earnings growth is anticipated. The main risk is the ongoing losses, with net income for Q2 2026 reported at -27.48 million USD, which raises concerns about financial stability and future viability.

Valuation Metrics

The current forward P/E ratio for Metagenomi Therapeutics Inc (MGX) is 0.00, compared to its 5-year average forward P/E of -1.29.

Forward P/E

Overvalued

5Y Average P/E

-1.29

Current P/E

0.00

Overvalued

-0.38

Undervalued

-2.21

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.08

Current EV/EBITDA

0.03

Overvalued

1.77

Undervalued

-1.60

Forward P/S

Fair

5Y Average P/S

3.86

Current P/S

3.69

Overvalued

5.89

Undervalued

1.83

MGX FAQ — answered by Alphio AI

Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. It discovers and develops a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. It focuses on value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Its lead candidate, MGX-001, is a wholly-owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to insert a Factor VIII (FVIII) DNA cassette into a safe harbor location within an intron of the albumin gene. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Metagenomi Inc (MGX) is not a good buy right now due to its significant financial struggles and negative market sentiment. The current price is $0.70, which is near its 52-week low of $0.60, reflecting a staggering year-to-date change of -57.99%. Additionally, the RSI is at 26.455, indicating that the stock is oversold, but this does not guarantee a rebound. The company reported a Q1 EPS of -0.61, missing expectations, and has a forward P/E ratio of 0, suggesting no earnings growth is anticipated. The main risk is the ongoing losses, with net income for Q2 2026 reported at -27.48 million USD, which raises concerns about financial stability and future viability.